Mizuho cuts Boston Scientific stock target to USD 55.00
Published on 10/14/2026 at 09:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTarget reset before third quarter
- Mizuho kept Outperform while cutting its target from USD 60.00 to USD 55.00 on October 13, 2026.
- Second-quarter revenue reached USD 5.44 billion, up 7.50 percent year over year.
- Boston Scientific stock traded at EUR 38.73 at 9:11 a.m. CEST on October 14, 2026.
Boston Scientific stock (ISIN US1011371077) was at the center of a fresh analyst reset after Markets Insider reported on October 13, 2026 that Mizuho lowered its Boston Scientific target from USD 60.00 to USD 55.00 while keeping an Outperform rating. The report linked the revision to a third-quarter earnings preview and expected procedure-volume pressure from changes involving the Affordable Care Act and Medicaid.
What does the target cut change?
The revised target preserves a positive rating but places more weight on near-term execution. Mizuho's USD 5.00 reduction is a 8.33 percent cut from the former USD 60.00 target, calculated against the previous target.
The timing matters because Boston Scientific is scheduled to report its third-quarter results on October 28, 2026. The next report will give investors a fresh test of procedure volumes and the company's operating outlook.
Revenue still grew in the second quarter
Boston Scientific reported USD 5.442 billion in net sales for the second quarter of 2026, up 7.50 percent on a reported basis and 7.00 percent on an operational basis. The company also reported adjusted earnings per share of USD 0.86 for the period, up 15.00 percent from the second quarter of 2025, according to Yahoo Finance.
The mix remains important for the next update. Revenue growth provides a measurable base, while the Mizuho note identifies procedure volume as a counter-factor that could affect the pace of improvement in the second half of 2026.
Operating structure changes in 2027
Boston Scientific announced on October 7, 2026 that Joseph M. Fitzgerald would become executive vice president and chief operating officer on January 1, 2027. The company release said the new structure will establish three reportable segments: Interventional Therapies, Rhythm Solutions and MedSurg.
Stock trades at a live European quote
Boston Scientific was trading at EUR 38.73 at Lang & Schwarz on October 14, 2026 at 9:11 a.m. CEST. The NYSE-listed stock was last at USD 43.31 on October 13, 2026 at 4:00 p.m. ET, while its 52-week range was USD 41.39 to USD 105.65.
The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.
Boston Scientific stock facts
- Company: Boston Scientific Corporation
- ISIN: US1011371077
- WKN: 884113
- Ticker: BSX
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 14, 2026, 9:11 a.m. CEST): EUR 38.73
- Market capitalization: USD 64.4 billion (as of October 13, 2026)
- 52-week range: USD 41.39-105.65 (as of October 13, 2026)
- Sector / Industry: Health Care / Medical Instruments and Supplies
- Next earnings date: October 28, 2026
Market context: Market report S&P 500.
